- Home
- MTEK vs RDHL Comparison
MTEK vs RDHL Comparison
Compare MTEK & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTEK | RDHL |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 4.0M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MTEK | RDHL |
|---|---|---|
| Price | $1.02 | $0.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.5K | ★ 2.6M |
| Earning Date | 05-12-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.94 | $0.57 |
| 52 Week High | $4.27 | $2.79 |
Technical Indicators
Market Signals| Indicator | MTEK | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 42.50 |
| Support Level | $0.97 | N/A |
| Resistance Level | $1.13 | $0.85 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 20.21 | 1.69 |
Price Performance
Historical ComparisonAbout MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.